Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
Myriad Genetics is expanding its companion diagnostics partnership with AstraZeneca, planning to use Myriad's BRACAnalysis test to see which metastatic pancreatic cancer patients respond to AstraZeneca's Lynparza (olaparib).
Dako is extending its collaboration with pharma giant Amgen to develop companion diagnostic products for drug development and research. Neither side is revealing financial details, but Dako, now an Agilent company, said the deal will focus on personalized medicine and tests that pair patients with suitable treatments.
HalioDx, a new company focused on cancer companion diagnostics, is kicking off operations after a management buyout at Qiagen's Marseille subsidiary.
Myriad Genetics expanded its partnership with BioMarin Pharmaceutical to use Myriad's myChoice HRD companion diagnostic test to identify which cancer patients are the best fit for BioMarin's talazoparib.
Denmark's Dako is teaming up with Ono Pharmaceutical to develop a test for Ono and Bristol-Myers Squibb's drug for non-small cell lung cancer, Opdivo, adding to its tally of companion diagnostics partnerships and gaining more ground in the field.
Abbott Laboratories' diagnostics unit charted sizable gains in 2014, and the company is continuing its upward momentum in the new year with an exclusive licensing deal with the Institut Curie.
ImmusanT roped in $12 million in Series B financing to beef up development of its companion diagnostic tests and vaccine for celiac disease, giving the company a much-needed boost as it forges ahead with R&D for its product.
A pair of European diagnostics companies have wrapped up venture financings. Autoimmune diagnostician Protagen had a first close of a €10 million ($12.5 million) financing, while cancer genomic diagnostics company, 14M Genomics, a spinout of the Wellcome Trust Sanger Institute, got £12.5 million ($19.6 million).
Singapore's government is teaming up with Thermo Fisher and other heavyweights in the biomedical space to accelerate the development and commercialization of new diagnostic tests.